Pharmacologic Therapy for the Hyperlipidemic Patient

    Requests for reprints should be addressed to Dr. Donald B. Hunninghake, Department of Pharmacology, 3-260 Millard Hall, University of Minnesota, Minneapolis, Minnesota 55455
    Department of Medicine and Pharmacology and Lipid Research Clinic, University of Minnesota Medical School, Minneapolis, Minnesota
    Search for articles by this author
      Drug therapy should be Instituted only after appropriate diet treatment has been started and adequate baseline lipid and lipoprotein values are established. Nicotinic acid is useful in treating most lipoprotein disorders and the cutaneous flushing that develops during the early part of treatment is usually alleviated by aspirin. Cholestyramine and colestipol are nonabsorbable resins whose use is limited to type II hyperlipoproteinemia. Clofibrate is primarily effective in lowering triglyceride levels, but its clinical use has considerably declined following the World Health Organization study results that reported increased morbidity and mortality rates among patients receiving this drug. Based on the finding of increased mortality among a subset of patients participating In the Coronary Drug Project, dextrothyroxine is only recommended for treating patients who do not have clinically evident atherosclerotic heart disease. Probucol lowers total and low-density lipoprotein cholesterol levels, but has the undesirable effect of simultaneously reducing high-density lipoprotein levels.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Report from the Committee of Principal Investigators: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate.
        Br Heart J. 1978; 40: 1069-1118
        • The Coronary Drug Project
        Findings leading to further modification of its protocol with respect to dextrothyroxine. The coronary drug project research group.
        JAMA. 1972; 220: 996-1008
        • Miettinin TA
        • Huttunen JK
        • Strandberg T
        • Naukkarinen V
        • Mattila S
        • Kumlin T
        Lowered HDL cholesterol and incidence of ischemic heart disease [letter].
        Lancet. 1981; II: 478
        • Baker SG
        • Joffe Bl
        • Mendelshon D
        • Seftel HD
        Treatment of homozygous familial hypercholesterolaemia with probucol.
        S Afr Med J. 1982; 62: 7-11